China today faces a dilemma in healthcare development between the present and the future. A fundamental choice will need to be made between financial incentives for future medical innovation or price controls that broaden present access to care
This spring, the world watched closely as Chinese officials responded rapidly to a new avian flu virus. In addition to closing poultry markets and monitoring patients, Chinese physicians and public health leaders are collaborating with international experts and the World Health Organisation. China’s healthcare system is demonstrating far greater capacity and responsiveness than in the 2003 SARS scare.
_
Clinical Trial Innovation[Reprinted with permission from The China Europe International Business School.]